Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relapsing-remitting

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    297 result(s) found for: Relapsing-remitting. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-002637-11 Sponsor Protocol Number: CFTY720DDE19 Start Date*: 2012-10-15
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated pa...
    Medical condition: Treatment statisfaction in patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000092-62 Sponsor Protocol Number: LPS13650 Start Date*: 2014-07-30
    Sponsor Name:Genzyme Corporation
    Full Title: Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtr...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004223-38 Sponsor Protocol Number: GEN414/OMS115102 Start Date*: 2009-01-05
    Sponsor Name:GlaxoSmithKline UK
    Full Title: A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DK (Completed) DE (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003265-19 Sponsor Protocol Number: LTS13840 Start Date*: 2015-05-12
    Sponsor Name:Genzyme Corporation
    Full Title: A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002305-23 Sponsor Protocol Number: SM3 Start Date*: 2008-02-05
    Sponsor Name:R&D Addenbrookes Hospital
    Full Title: A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3.
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003696-12 Sponsor Protocol Number: 109MS301 Start Date*: 2007-03-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) AT (Completed) SE (Prematurely Ended) NL (Completed) GR (Completed) IT (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004751-20 Sponsor Protocol Number: PB006-03-01 Start Date*: 2019-07-22
    Sponsor Name:Polpharma Biologics S.A.
    Full Title: Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001442-15 Sponsor Protocol Number: CFTY720D2324 Start Date*: 2011-08-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from...
    Medical condition: relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) ES (Completed) GR (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) FI (Prematurely Ended) HU (Completed) SE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000728-97 Sponsor Protocol Number: EMR200109_635 Start Date*: Information not available in EudraCT
    Sponsor Name:Academic MS Center Limburg
    Full Title: Regulation of the stress-axis by vitamin D3 in subjects with multiple sclerosis; a double-blinded, randomized, placebo-controlled study
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002324-16 Sponsor Protocol Number: CVAY736X2202 Start Date*: 2014-06-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with rel...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005160-41 Sponsor Protocol Number: ALK8700-A301 Start Date*: 2016-07-27
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) PL (Completed) ES (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020328-23 Sponsor Protocol Number: EMR200136-532 Start Date*: 2010-10-21
    Sponsor Name:Merck Serono
    Full Title: A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sc...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) DE (Completed) DK (Completed) BE (Prematurely Ended) IT (Completed) LT (Completed) EE (Completed) LV (Completed) AT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001958-99 Sponsor Protocol Number: 100207MSH Start Date*: 2007-12-18
    Sponsor Name:Merja Soilu Häninen
    Full Title: Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS
    Medical condition: Patients with relapsing remitting MS according to the revised Mc Donald's criteria who meet all criteria for inclusion and none criteria of exclusion.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018705-11 Sponsor Protocol Number: ONO-4641POU007 Start Date*: 2010-09-13
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) CZ (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004059-29 Sponsor Protocol Number: GNC-003 Start Date*: 2016-05-04
    Sponsor Name:GeNeuro SA
    Full Title: An international, double-blind, randomised, placebo-controlled phase IIb trial to assess the efficacy, safety, and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) ES (Completed) EE (Completed) PL (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006786-92 Sponsor Protocol Number: AC-058B201 Start Date*: 2009-06-18
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor ...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) FR (Completed) GB (Completed) ES (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed) IT (Completed) AT (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-002145-11 Sponsor Protocol Number: 101MS329 Start Date*: 2019-03-21
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Rela...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) NL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007459-28 Sponsor Protocol Number: H9B-MC-BCDJ(b) Start Date*: 2009-10-08
    Sponsor Name:Eli Lilly and Company
    Full Title: Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FI (Completed) HU (Completed) CZ (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-011626-34 Sponsor Protocol Number: CAIN457B2201 Start Date*: 2009-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 2...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-003647-30 Sponsor Protocol Number: LAQ-MS-305 Start Date*: 2013-01-18
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two dos...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) LV (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) EE (Prematurely Ended) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 15:11:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA